Abeona Therapeutics sells PRV for $155M cash; expects profitability early 2026

ABEONA THERAPEUTICS INC.

Definitive agreement to sell Rare Pediatric Disease PRV for $155M in gross cash proceeds at closing.
PRV awarded by FDA on April 28, 2025 upon approval of ZEVASKYN (prademagene zamikeracel) for RDEB.
CFO: proceeds provide over two years of operating expenses without additional financing; ZEVASKYN launch Q3 2025.
Expects profitability in early 2026; closing subject to HSR waiting period; Stifel and Jefferies as advisors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.